Supplementary Figure S5 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma

Yang Yu,Yupei Zhao,Fan Ye,Zhenghu Chen,Hui Li,Jian Lu,Kevin Guo,Sarah E. Woodfield,Sanjeev A. Vasudevan,Jing Yang,Jed G. Nuchtern

DOI: https://doi.org/10.1158/1535-7163.22506219

2023-01-01

Abstract:Correlation between USP14 and NB patients' outcomes.

What problem does this paper attempt to address?

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Tingyu Wu,Wei Chen,Yongwang Zhong,Xiaodan Hou,Shengyun Fang,Chen-Ying Liu,Guanghui Wang,Tong Yu,Yu-Yang Huang,Xuesong Ouyang,Henry Q.X. Li,Long Cui,Yili Yang

DOI: https://doi.org/10.1158/1535-7163.22507968.v1

2023-01-01

Abstract:Bortezomib and KPT330 co-treatment inhibit patients-derived xenografts in nude mice.
A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways

J Cheng,Y-H Fan,X Xu,H Zhang,J Dou,Y Tang,X Zhong,Y Rojas,Y Yu,Y Zhao,S A Vasudevan,H Zhang,J G Nuchtern,E S Kim,X Chen,F Lu,J Yang

DOI: https://doi.org/10.1038/cddis.2014.54

2014-01-01

Abstract:Neuroblastoma (NB) is the most common extracranial neoplasm in children. In NB, loss of p53 function is largely due to cytoplasmic sequestration rather than mutation. Ubiquitin-conjugating enzyme E2 N (UBE2N), also known as Ubc13, is an E2 ubiquitin-conjugating enzyme that promotes formation of monomeric p53 that results in its cytoplasmic translocation and subsequent loss of function. Therefore, inhibition of UBE2N may reactivate p53 by promoting its nuclear accumulation. Here, we show that NSC697923, a novel UBE2N inhibitor, exhibits potent cytotoxicity in a panel of NB cell lines evidenced by its ability to induce apoptosis. In p53 wild-type NB cells, NSC697923 induced nuclear accumulation of p53, which led to its increased transcriptional activity and tumor suppressor function. Interestingly, in p53 mutant NB cells, NSC697923 induced cell death by activating JNK pathway. This effect was reversible by blocking JNK activity with its selective inhibitor, SP600125. More importantly, NSC697923 impeded cell growth of chemoresistant LA-N-6 NB cell line in a manner greater than conventional chemotherapy drugs doxorubicin and etoposide. NSC697923 also revealed in vivo antitumor efficacy in NB orthotopic xenografts. Taken together, our results suggest that UBE2N is a potential therapeutic target in NB and provide a basis for the rational use of UBE2N inhibitors like NSC697923 as a novel treatment option for NB patients.
Supplementary Fig.4 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Tingyu Wu,Wei Chen,Yongwang Zhong,Xiaodan Hou,Shengyun Fang,Chen-Ying Liu,Guanghui Wang,Tong Yu,Yu-Yang Huang,Xuesong Ouyang,Henry Q.X. Li,Long Cui,Yili Yang

DOI: https://doi.org/10.1158/1535-7163.22507974.v1

2023-01-01

Abstract:Nuclear p53 plays a critical role in synergistic cytotoxic effect in RKO cells.
Downregulation of Ubiquitin-Specific Protease 14 (USP14) Inhibits Breast Cancer Cell Proliferation and Metastasis, but Promotes Apoptosis

Lianxin Zhu,Shuyun Yang,Song He,Fulin Qiang,Jing Cai,Rong Liu,Changjiang Gu,Zengya Guo,Chen Wang,Wei Zhang,Chunhui Zhang,Yingying Wang

DOI: https://doi.org/10.1007/s10735-015-9650-3

2015-01-01

Journal of Molecular Histology

Abstract:Breast cancer is the second leading cause of cancer-related death in women. Previously, evidence suggested that ubiquitin-specific protease 14 (USP14) was associated with various signal transduction pathways and tumourigenesis. In this study, we demonstrate that USP14 is a novel therapeutic target in breast cancer. A Western blot analysis of USP14 was performed using seven breast cancer tissues and paired adjacent normal tissues and showed that the expression of USP14 was increased in the breast cancer tissues. Immunohistochemistry was conducted on formalin-fixed paraffin-embedded sections of breast cancer samples from 100 cases. Using Pearson’s χ2 test, it was demonstrated that USP14 expression was associated with the histological grade, lymph node status and Ki-67 expression in the tumour. The Kaplan–Meier analysis revealed that increased USP14 expression in patients with breast cancer was associated with a poorer prognosis. In in vitro experiments, the highly migratory MDA-MB-231 cells that were treated with USP14-shRNA (shUSP14) exhibited decreased motility using Transwell migration assays. Next, we employed a starvation and re-feeding assay, and the CCK-8 assay demonstrated that USP14 regulated breast cancer cell proliferation. Furthermore, we used flow cytometry to analyse cellular apoptosis following USP14 knockdown. Taken together, our results suggested that USP14 was involved in the progression of breast cancer.
Identification of USP29 as a key regulator of nucleotide biosynthesis in neuroblastoma through integrative analysis of multi-omics data

Ye Kang,Yahuan Yu,Yijia Liu,Yiwen Pan,Ru Zhang,Doudou Ren,Zeqiong Cai,Junpeng Ma,Xiaofan Xiong,Qi Zhang,Chengsheng Zhang,Rongfu Tu

DOI: https://doi.org/10.1080/15384047.2023.2237200

2023-07-20

Abstract:Cancer cells show enhanced nucleotide biosynthesis, which is essential for their unlimited proliferation, but the underlying mechanisms are not entirely clear. Ubiquitin specific peptidase 29 (USP29) was reported to sustain neuroblastoma progression by promoting glycolysis and glutamine catabolism; however, its potential role in regulating nucleotide biosynthesis in tumor cells remains unknown. In this study, we depleted endogenous USP29 in MYCN -amplified neuroblastoma SK-N-BE2 cells by sgRNAs and conducted metabolomic analysis in cells with or without USP29 depletion, we found that USP29 deficiency caused a disorder of intermediates involved in glycolysis and nucleotide biosynthesis. De novo nucleotide biosynthesis was analyzed using 13 C 6 glucose as a tracer under normoxia and hypoxia. The results indicated that USP29 -depleted cells showed inhibition of nucleotide anabolic intermediates derived from glucose, and this inhibition was more significant under hypoxic conditions. Analysis of RNA sequencing data in SK-N-BE2 cells demonstrated that USP29 promoted the gene expression of metabolic enzymes involved in nucleotide anabolism, probably by regulating MYC and E2F downstream pathways. These findings indicated that USP29 is a key regulator of nucleotide biosynthesis in tumor cells.

oncology
Ubiquitin-specific Protease 22 is Associated with Poor Prognosis in Neuroblastoma.

Qu Zhibo,Liu Lianxin

DOI: https://doi.org/10.17219/acem/115089

2020-01-01

Advances in Clinical and Experimental Medicine

Abstract:BACKGROUND:Ubiquitin-specific protease 22 (USP22) alters histone ubiquitination and is considered to be an oncogenic factor involved in tumor progression. The USP22 aberrance has been implicated in several malignancies, but whether USP22 plays a role in neuroblastoma (NB) remains unclear. To the best of our knowledge, the clinicopathological significance of USP22 expression in NB has not been previously reported in the English-language medical literature.OBJECTIVES:The aim of this study was to investigate the role of USP22 and its association with potential targets in patients with NB.MATERIAL AND METHODS:The potential clinicopathological significance of USP22 expression in NB was studied using immunohistochemistry, immunohistochemical staining assessment and statistical analyses.RESULTS:Based on the immunohistochemical analysis, the USP22 protein was detected more manifestly in NB tissues than in healthy peritumoral tissue. Furthermore, an association between USP22, lymph node metastasis and NB clinical stage was observed, whereby the level of USP22 protein was higher in stage III-IV specimens than in stage I-II specimens (p < 0.05). Furthermore, tumors expressing USP22 were associated with poorer patient prognosis than the USP22-negative tumors. The multivariate Cox regression analysis suggested that the level of USP22 protein is a predictive factor for survival (p < 0.05).CONCLUSIONS:Our results indicate a significant association between USP22 level and poor prognosis in NB. Thus, USP22 represents a valuable biomarker for predicting the outcome of patients with NB.
Supplementary Figure 5 from Evidence for the Ubiquitin Protease UBP43 As an Antineoplastic Target

Yongli Guo,Fadzai Chinyengetere,Andrey V. Dolinko,Alexandra G. Lopez‐Aguiar,Yun Lu,Fabrizio Galimberti,Tao Ma,Feng Qi,David Sekula,Sarah J. Freemantle,Angeline S. Andrew,Vincent A. Memoli,Ethan Dmitrovsky

DOI: https://doi.org/10.1158/1535-7163.22498662

2023-01-01

Abstract:PDF file, 166K, Repression of UBP43 mRNA inhibits in vivo and in vitro growth of ED1 lung cancer cells.
Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer

Ying Zhu,Chaoxiong Zhang,Changxin Gu,Qiang Li,Ning Wu

DOI: https://doi.org/10.1159/000443051

2016-01-01

Cellular Physiology and Biochemistry

Abstract:Background/Aims: Non-small cell lung cancer (NSCLC) tissues overexpress USP14, which promotes tumor cell proliferation and is associated with shorter overall survival time. Methods: The expression of USP14 was assayed in many types of cancers. USP14 was up-and down-regulated using appropriate plasmid or lentiviral vector constructs and its effects on proliferation, cell colony number, and apoptosis rate were measured. A human NSCLC cell line was inoculated into nude mice and the survival rates were recorded. Results: We found USP14 amplification and overexpression in many different cancers. The overexpression of USP14 in USP14 low-expression cell lines promoted cell proliferation and migration, whereas USP14 downregulation suppressed tumor cell proliferation, decreased tumor cell colony number, increased apoptosis rate, and decreased cell migration and invasion. Conclusion: USP14 plays an oncogenic role in various types of cancer, and may thus represent a new cancer therapy target.
Abstract 5988: The role of the deubiquitinase USP7 and the E3/E4 ubiquitin ligase complex ITCH/UBE4B in the regulation of cell death in neuroblastoma

Christophe Le Clorennec,CARLA SAMPAIO,PETER E. ZAGE

DOI: https://doi.org/10.1158/1538-7445.am2024-5988

IF: 11.2

2024-03-24

Cancer Research

Abstract:Dysregulation of the Ubiquitin Proteasome System has been linked to many human diseases, including cancer. Expression of UBE4B ubiquitin ligase is associated with neuroblastoma patient outcomes and its functional roles in neuroblastoma pathogenesis are not known. We have recently identified a ubiquitin complex ITCH/UBE4B which mediates ubiquitination of Ku70 and c-FLIPL proteins for proteasomal degradation allowing HDAC inhibitor-mediated caspase-8 dependent apoptosis. We also confirmed that the deubiquitinase USP7, critical player in tumor suppression and DNA repair, can be a potential therapeutic target for neuroblastoma. Highly selective USP7 inhibitors have demonstrated significant antitumor activity in preclinical models of adult cancer, and we reported that these inhibitors alone can be more effective against neuroblastoma tumor growth. Our hypothesis is that USP7 inhibition will be more effective against neuroblastoma tumors through destabilization of ITCH/UBE4B complex protein targets allowing a stronger induction of cell death in response to treatment for the children. To evaluate efficacy of USP7 inhibitors in combination with HDAC inhibitors or chemotherapy against neuroblastoma tumor growth, neuroblastoma cell lines depleted for UBE4B or USP7 were treated with increasing concentrations of USP7 inhibitors alone or in combination with chemotherapy or with HDAC inhibitors. Cell proliferation was measured using continuous live cell imaging and apoptosis by caspase cleavage and PARP cleavage detection by western blot. We have evaluated also, whether ubiquitination/deubiquitination and degradation rates of p53, Ku70 and c-FLIPL proteins could modulate induction of apoptosis and necroptosis. USP7 inhibition resulted in decreases in cell viability in p53 wild-type neuroblastoma cell lines. USP7 inhibition induced apoptosis and necroptosis by increasing phosphorylation of MLKL, RIPK3 and RIPK1. In UBE4B or USP7 depleted cells, a huge induction of necroptosis and a small rate of apoptosis were observed. We also identified USP7 as a deubiquitinase of Ku70, stabilizing Ku70 at the basal level, leading to stabilization of Ku70/c-FLIPL/Bax complex. USP7 inhibition destabilizes ku70 and c-FLIPL for protein degradation leading to induction of apoptosis as well as necroptosis. UBE4B depletion in neuroblastoma inhibits HDAC inhibitors mediated caspase-8 mediated apoptosis but enhances necroptosis, due to the inhibition of Ku70 and c-FLIPL proteins degradation leading to the blockade of caspase-8 activation and the activation of the necroptosome. Our data suggests that USP7 and ITCH/UBE4B can control the switch between apoptosis and necroptosis in response to USP7 and HDAC inhibitors. USP7 inhibition and ITCH/UBE4B activation by HDAC inhibitors could be a promising therapeutic strategy for children with high-risk and relapsed neuroblastoma. Citation Format: Christophe Le Clorennec, CARLA SAMPAIO, PETER E. ZAGE. The role of the deubiquitinase USP7 and the E3/E4 ubiquitin ligase complex ITCH/UBE4B in the regulation of cell death in neuroblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5988.

oncology
Supplementary Figure S4 from Targeted Therapy of &Lt;i>tert-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Jingwei Chen,Christopher P. Nelson,Matthew Wong,Andrew E. Tee,Pei Y. Liu,Ting La,Jamie I. Fletcher,Alvin Kamili,Chelsea Mayoh,Christoph Bartenhagen,Toby N. Trahair,Ning Xu,Nisitha Jayatilleke,Marie Wong,Pei Hui,Bernard Atmadibrata,Belamy B. Cheung,Qing Lan,Tracy M. Bryan,Pieter Mestdagh,Jo Vandesompele,Valérie Combaret,Valentina Boeva,Jenny Wang,Isabelle Janoueix-Lerosey,Mark J. Cowley,Karen L. MacKenzie,Alla Dolnikov,Jinyan Li,Patsie Polly,Glenn M. Marshall,Roger R. Reddel,Murray D. Norris,Michelle Haber,Matthias Fischer,Xu Dong Zhang,Hilda A. Pickett,Tao Liu

DOI: https://doi.org/10.1158/1078-0432.22479843.v1

2023-01-01

Abstract:Supplementary Figure S4. Combination of the BET bromodomain inhibitor I-BET762 and chemotherapy agents, but not proteasome inhibitors, induces cytotoxicity to normal cells.
Inhibition of USP14 promotes TNFα-induced cell death in head and neck squamous cell carcinoma (HNSCC)

Ethan L. Morgan,Tiffany Toni,Ramya Viswanathan,Yvette Robbins,Xinping Yang,Hui Cheng,Sreenivasulu Gunti,Angel Huynh,Anastasia L. Sowers,James B. Mitchell,Clint T. Allen,Zhong Chen,Carter Van Waes

DOI: https://doi.org/10.1038/s41418-023-01144-x

IF: 12.067

2023-04-14

Cell Death and Differentiation

Abstract:TNFα is a key mediator of immune, chemotherapy and radiotherapy-induced cytotoxicity, but several cancers, including head and neck squamous cell carcinomas (HNSCC), display resistance to TNFα due to activation of the canonical NFκB pro-survival pathway. However, direct targeting of this pathway is associated with significant toxicity; thus, it is vital to identify novel mechanism(s) contributing to NFκB activation and TNFα resistance in cancer cells. Here, we demonstrate that the expression of proteasome-associated deubiquitinase USP14 is significantly increased in HNSCC and correlates with worse progression free survival in Human Papillomavirus (HPV)- HNSCC. Inhibition or depletion of USP14 inhibited the proliferation and survival of HNSCC cells. Further, USP14 inhibition reduced both basal and TNFα-inducible NFκB activity, NFκB-dependent gene expression and the nuclear translocation of the NFκB subunit RELA. Mechanistically, USP14 bound to both RELA and IκBα and reduced IκBα K48-ubiquitination leading to the degradation of IκBα, a critical inhibitor of the canonical NFκB pathway. Furthermore, we demonstrated that b-AP15, an inhibitor of USP14 and UCHL5, sensitized HNSCC cells to TNFα-mediated cell death, as well as radiation-induced cell death in vitro. Finally, b-AP15 delayed tumor growth and enhanced survival, both as a monotherapy and in combination with radiation, in HNSCC tumor xenograft models in vivo, which could be significantly attenuated by TNFα depletion. These data offer new insights into the activation of NFκB signaling in HNSCC and demonstrate that small molecule inhibitors targeting the ubiquitin pathway warrant further investigation as a novel therapeutic avenue to sensitize these cancers to TNFα- and radiation-induced cytotoxicity.

cell biology,biochemistry & molecular biology
Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Xing Huang,Qi Zhang,Yu Lou,Junli Wang,Xinyu Zhao,Lin Wang,Xiaozhen Zhang,Shanshan Li,Yulan Zhao,Qi Chen,Tingbo Liang,Xueli Bai

DOI: https://doi.org/10.1158/2326-6066.22542111.v1

2023-01-01

Abstract:This file contains supplemental figures S1-S8, and the detailed description is as follows: Figure S1 shows USP22 binding to HLEET motif of CD274. Figure S2 shows USP22 stabilizing CD274 in CDK4-independent manner. Figure S3 shows the non-requirement of CD274 for USP22-controlled cancer cell growth in vitro. Figure S4 shows the expression profile of USP22 in multiple cancers. Figure S5 shows the CD274-independent roles of USP22 in liver cancer growth and therapy. Figure S6 shows the expression levels of CD274 in USP22-regulated tumor immunity. Figure S7 shows the negative correlation of USP22 and immune signatures in LIHC. Figure S8 shows the schematic model.
Supplementary Figure S6 from Targeted Therapy of &Lt;i>tert-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Jingwei Chen,Christopher P. Nelson,Matthew Wong,Andrew E. Tee,Pei Y. Liu,Ting La,Jamie I. Fletcher,Alvin Kamili,Chelsea Mayoh,Christoph Bartenhagen,Toby N. Trahair,Ning Xu,Nisitha Jayatilleke,Marie Wong,Pei Hui,Bernard Atmadibrata,Belamy B. Cheung,Qing Lan,Tracy M. Bryan,Pieter Mestdagh,Jo Vandesompele,Valérie Combaret,Valentina Boeva,Jenny Wang,Isabelle Janoueix-Lerosey,Mark J. Cowley,Karen L. MacKenzie,Alla Dolnikov,Jinyan Li,Patsie Polly,Glenn M. Marshall,Roger R. Reddel,Murray D. Norris,Michelle Haber,Matthias Fischer,Xu Dong Zhang,Hilda A. Pickett,Tao Liu

DOI: https://doi.org/10.1158/1078-0432.22479837.v1

2023-01-01

Abstract:Supplementary Figure S6. OTX015 and carfilzomib exert synergistic anticancer effects partly by inducing oxidative stress and endoplasmic reticulum stress.
The Deubiquitinase USP28 Maintains the Expression of the Transcription Factor MYCN and is Essential in Neuroblastoma Cells.

Junjun Li,Jin Peng,Lingzhi Wu,Xiang Shen,Xinghua Zhen,Yimao Zhang,Huailu Ma,Yongfeng Xu,Qunli Xiong,Qing Zhu,Pumin Zhang

DOI: https://doi.org/10.1016/j.jbc.2023.104856

2023-01-01

Abstract:Neuroblastoma (NB) is one of the most common extracranial solid tumors in children. MYCN gene amplification is highly associated with poor prognosis in high-risk NB patients. In non-MYCN-amplified high-risk NB patients, the expression of c-MYC (MYCC) and its target genes is highly elevated. USP28 as a deubiquitinase is known to regulate the stability of MYCC. We show here USP28 also regulates the stability of MYCN. Genetic depletion or pharmacologic inhibition of the deubiquitinase strongly destabilizes MYCN and stops the growth of NB cells that overexpress MYCN. In addition, MYCC could be similarly destabilized in non-MYCN NB cells by compromising USP28 function. Our results strongly suggest USP28 as a therapeutic target for NB with or without MYCN amplification/overexpression.
Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin.

Ning Wu,Cong Liu,Chong Bai,Yi-Ping Han,William C S Cho,Qiang Li

DOI: https://doi.org/10.3390/ijms140610749

IF: 5.6

2013-01-01

International Journal of Molecular Sciences

Abstract:The deubiquitinating enzyme USP14 has been identified and biochemically studied, but its role in lung cancer remains to be elucidated. The aim of this study was to evaluate the prognostic significance of USP14 in patients with lung adenocarcinoma and to define its role in lung cancer cell proliferation. USP14 mRNA levels in different non-small cell lung cancer (NSCLC) cell lines were detected by real-time qPCR. USP14 protein levels in surgically resected samples from NSCLC patients, and in NSCLC cell lines, were detected by immunohistochemistry or Western blot. The correlation of USP14 expression with clinical characteristics and prognosis was determined by survival analysis. After silencing USP14, cell proliferation was assessed by MTT assay and the cell cycle was measured by FACS assay. It was found that USP14 expression was upregulated in NSCLC cells, especially in adenocarcinoma cells. Over-expression of USP14 was associated with shorter overall survival of patients. Downregulation of USP14 expression arrested the cell cycle, which may be related to β-catenin degradation. Over-expression of USP14 was associated with poor prognosis in NSCLC patients and promoted tumor cell proliferation, which suggests that USP14 is a tumor-promoting factor and a promising therapeutic target for NSCLC.
Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

Monika Lukoseviciute,Stefan Holzhauser,Eleni Pappa,Tamoghna Mandal,Tina Dalianis,Ourania N. Kostopoulou,Ourania Kostopoulou

DOI: https://doi.org/10.3892/or.2023.8603

2023-07-21

Oncology Reports

Abstract:Neuroblastoma (NB), the most frequent solid extracranial tumor in children, is not always cured by current aggressive therapies that have notable adverse effects; therefore, novel treatments are necessary. Phosphoinositide 3‐kinase (PI3K) and fibroblast growth factor receptor inhibitors exhibit synergistic effect in NB cell lines. In the present study, mono‐ and combination therapy of the United States Food and Drug Administration‐approved PI3K, cyclin‐dependent kinase‐4/6 (CDK4/6), poly‐ADP‐ribose‐polymerase (PARP) and WEE1 G2 checkpoint kinase (WEE1) inhibitors (BYL719, PD‐0332991, BMN673 and MK‐1775, respectively), were used to treat NB cell lines SK‐N‐AS, SK‐N‐BE(2)‐C, SK‐N‐DZ, SK‐N‐FI and SK‐N‐SH and viability (assessed by WST‐1 assay), proliferation (incucyte analysis) and cell cycle (FACS) changes were assessed. Treatments with all single drugs presented dose‐dependent responses with decreased viability and proliferation and combining BYL719 with PD‐0332991 or BMN673 with MK‐1775 resulted in additive or synergistic effects in most cell lines., except for SK‐N‐SH for the former and for SK‐N‐AS for the latter. Moreover, combining MK‐1775 and BMN673 decreased the numbers of cells in S phase to a greater extent than either drug alone, while when combining PD‐0332991 and BYL719 the observed effect was close to that of PD‐0332991 alone. To summarize, PI3K and CDK4/6 or PARP and WEE1 exhibited synergistic anti‐NB effects and lower doses of the inhibitors could be utilized, thereby potentially reducing adverse side effects.

oncology
Supplementary Figure S7 from Targeted Therapy of &Lt;i>tert-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Jingwei Chen,Christopher P. Nelson,Matthew Wong,Andrew E. Tee,Pei Y. Liu,Ting La,Jamie I. Fletcher,Alvin Kamili,Chelsea Mayoh,Christoph Bartenhagen,Toby N. Trahair,Ning Xu,Nisitha Jayatilleke,Marie Wong,Pei Hui,Bernard Atmadibrata,Belamy B. Cheung,Qing Lan,Tracy M. Bryan,Pieter Mestdagh,Jo Vandesompele,Valérie Combaret,Valentina Boeva,Jenny Wang,Isabelle Janoueix-Lerosey,Mark J. Cowley,Karen L. MacKenzie,Alla Dolnikov,Jinyan Li,Patsie Polly,Glenn M. Marshall,Roger R. Reddel,Murray D. Norris,Michelle Haber,Matthias Fischer,Xu Dong Zhang,Hilda A. Pickett,Tao Liu

DOI: https://doi.org/10.1158/1078-0432.22479834.v1

2023-01-01

Abstract:Supplementary Figure S7. OTX015 and carfilzomib synergistically improve mouse survival in a PDX model of TERT-rearranged neuroblastoma.
Novel Src/Abl Tyrosine Kinase Inhibitor Bosutinib Suppresses Neuroblastoma Growth Via Inhibiting Src/Abl Signaling

Shayahati Bieerkehazhi,Zhenghu Chen,Yanling Zhao,Yang Yu,Huiyuan Zhang,Sanjeev A. Vasudevan,Sarah E. Woodfield,Ling Tao,Joanna S. Yi,Jodi A. Muscal,Jonathan C. Pang,Shan Guan,Hong Zhang,Jed G. Nuchtern,Hui Li,Huiwu Li,Jianhua Yang

DOI: https://doi.org/10.18632/oncotarget.13643

2016-01-01

Oncotarget

Abstract:Neuroblastoma (NB) is the most common extracranial solid tumor in children. Aberrant activation of the non-receptor tyrosine kinases Src and c-Abl contributes to the progression of NB. Thus, targeting these kinases could be a promising strategy for NB therapy. In this paper, we report that the potent dual Src/Abl inhibitor bosutinib exerts anti-tumor effects on NB. Bosutinib inhibited NB cell proliferation in a dose-dependent manner and suppressed colony formation ability of NB cells. Mechanistically, bosutinib effectively decreased the activity of Src/Abl and PI3K/AKT/mTOR, MAPK/ERK, and JAK/STAT3 signaling pathways. In addition, bosutinib enhanced doxorubicin (Dox)- and etoposide (VP-16)-induced cytotoxicity in NB cells. Furthermore, bosutinib demonstrated anti-tumor efficacy in an orthotopic xenograft NB mouse model in a similar mechanism as of that in vitro. In summary, our results reveal that Src and c-Abl are potential therapeutic targets in NB and that the novel Src/Abl inhibitor bosutinib alone or in combination with other chemotherapeutic agents may be a valuable therapeutic option for NB patients.
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Si-Qi Jia,Ran Zhuo,Zi-Mu Zhang,Yang Yang,Yan-Fang Tao,Jian-Wei Wang,Xiao-Lu Li,Yi Xie,Gen Li,Di Wu,Yan-Ling Chen,Juan-Juan Yu,Zhi-Heng Li,Rong-Fang Zhou,Ran-Dong Yang,Peng-Cheng Yang,Bi Zhou,Xiao-Mei Wan,Yu-Meng Wu,Wan-Yan Jiao,Ni-Na Zhou,Fang Fang,Jian Pan,Chen-xi Feng

DOI: https://doi.org/10.1155/2022/7945884

IF: 4.4929

2022-11-18

Journal of Immunology Research

Abstract:Neuroblastoma (NB) is the most common solid tumor of the neural crest cell origin in children and has a poor prognosis in high-risk patients. The oncogene MYCN was found to be amplified at extremely high levels in approximately 20% of neuroblastoma cases. In recent years, research on the targeted hydrolysis of BRD4 to indirectly inhibit the transcription of the MYCN created by proteolysis targeting chimaera (PROTAC) technology has become very popular. dBET57 (S0137, Selleck, TX, USA) is a novel and potent heterobifunctional small molecule degrader based on PROTAC technology. The purpose of this study was to investigate the therapeutic effect of dBET57 in NB and its potential mechanism. In this study, we found that dBET57 can target BRD4 ubiquitination and disrupt the proliferation ability of NB cells. At the same time, dBET57 can also induce apoptosis, cell cycle arrest, and decrease migration. Furthermore, dBET57 also has a strong antiproliferation function in xenograft tumor models in vivo. In terms of mechanism, dBET57 targets the BET protein family and the MYCN protein family by associating with CRBN and destroys the SE landscape of NB cells. Combined with RNA-seq and ChIP-seq public database analysis, we identified the superenhancer-related genes TBX3 and ZMYND8 in NB as potential downstream targets of dBET57 and experimentally verified that they play an important role in the occurrence and development of NB. In conclusion, these results suggest that dBET57 may be an effective new therapeutic drug for the treatment of NB.

immunology

Supplementary Figure S5 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways

Supplementary Fig.4 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Downregulation of Ubiquitin-Specific Protease 14 (USP14) Inhibits Breast Cancer Cell Proliferation and Metastasis, but Promotes Apoptosis

Identification of USP29 as a key regulator of nucleotide biosynthesis in neuroblastoma through integrative analysis of multi-omics data

Ubiquitin-specific Protease 22 is Associated with Poor Prognosis in Neuroblastoma.

Supplementary Figure 5 from Evidence for the Ubiquitin Protease UBP43 As an Antineoplastic Target

Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer

Abstract 5988: The role of the deubiquitinase USP7 and the E3/E4 ubiquitin ligase complex ITCH/UBE4B in the regulation of cell death in neuroblastoma

Supplementary Figure S4 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Inhibition of USP14 promotes TNFα-induced cell death in head and neck squamous cell carcinoma (HNSCC)

Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Supplementary Figure S6 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

The Deubiquitinase USP28 Maintains the Expression of the Transcription Factor MYCN and is Essential in Neuroblastoma Cells.

Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin.

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

Supplementary Figure S7 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Novel Src/Abl Tyrosine Kinase Inhibitor Bosutinib Suppresses Neuroblastoma Growth Via Inhibiting Src/Abl Signaling

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Supplementary Figure S5 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways

Supplementary Fig.4 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Downregulation of Ubiquitin-Specific Protease 14 (USP14) Inhibits Breast Cancer Cell Proliferation and Metastasis, but Promotes Apoptosis

Identification of USP29 as a key regulator of nucleotide biosynthesis in neuroblastoma through integrative analysis of multi-omics data

Ubiquitin-specific Protease 22 is Associated with Poor Prognosis in Neuroblastoma.

Supplementary Figure 5 from Evidence for the Ubiquitin Protease UBP43 As an Antineoplastic Target

Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer

Abstract 5988: The role of the deubiquitinase USP7 and the E3/E4 ubiquitin ligase complex ITCH/UBE4B in the regulation of cell death in neuroblastoma

Supplementary Figure S4 from Targeted Therapy of &Lt;i&gt;tert&lt;/i&gt;-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Inhibition of USP14 promotes TNFα-induced cell death in head and neck squamous cell carcinoma (HNSCC)

Supplementary Figures S1-S8 from USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity

Supplementary Figure S6 from Targeted Therapy of &Lt;i&gt;tert&lt;/i&gt;-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

The Deubiquitinase USP28 Maintains the Expression of the Transcription Factor MYCN and is Essential in Neuroblastoma Cells.

Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin.

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

Supplementary Figure S7 from Targeted Therapy of &Lt;i&gt;tert&lt;/i&gt;-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Novel Src/Abl Tyrosine Kinase Inhibitor Bosutinib Suppresses Neuroblastoma Growth Via Inhibiting Src/Abl Signaling

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Supplementary Figure S4 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S6 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S7 from Targeted Therapy of &Lt;i>tert</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy